Global /South Korea /Healthcare /Biotechnology /263050

Eutilex.Co.,Ltd

263050

• KRX: 263050 • Delayed

959KRW 30%

0.6317 USD

As of 14 June 2026, Eutilex.Co.,Ltd has a market cap of $23.23M USD, ranking #36045 globally and #2274 in South Korea. It ranks #3240 in the Healthcare sector, and #630 in the Biotechnology industry.

Global Rank

36045

Country Rank

2274

Sector Rank

3240

Industry Rank

630

Key Stats

Market Cap

$23.23MUSD

35.32B KRW

Enterprise Value

$30.16MUSD

45.79B KRW

Revenue (TTM)

$6.77MUSD

10.29B KRW

EBITDA (TTM)

-$10.2MUSD

-15.49B KRW

Net Income (TTM)

-$15.73MUSD

-23.92B KRW

EBITDA Margin

-150%

Profit Margin

-232%

PS Ratio

3.4

PB Ratio

2.2

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Byoung-Se Kwon open_in_new

Founded

2008

Website

eutilex.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
30%	32%	-12%	-31%	-45%	-13%	-49%	-85%	-97%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	263050 (주)유틸렉스 Ordinary Shares ISIN: KR7263050007 Shares Out.: Shares Outstanding: 36.831M¹ Shares Float: 27.346M² TV: TradingView: KRX: 263050 SA: Stock Analysis: KRX: 263050 YF: Yahoo Finance: 263050.KS GF: Google Finance: KRX: 263050 BA: Barron's: 263050 MS: Morningstar: XKRX: 263050	959 KRW	TV: TradingView: KRX: 263050 SA: Stock Analysis: KRX: 263050 YF: Yahoo Finance: 263050.KS GF: Google Finance: KRX: 263050 BA: Barron's: 263050 MS: Morningstar: XKRX: 263050

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 193K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 121K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.37B 20.33T KRW 57K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.51B 8.37T KRW 24K%	-	South Korea
Peptron, Inc. KRX: 087010	$3.99B 6.07T KRW 17K%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.25B 3.42T KRW 10K%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 785K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 688K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 206K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 182K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 182K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 119K%	-	United States

chevron_leftBack